SynAct Pharma prepares move to Nasdaq Stockholm - English version - Published today at 17.31 CET
February 4, 2021 17:31 CET The Board of Directors of SynAct Pharma AB (“SynAct Pharma” or the “Company”) has decided to evaluate the conditions and begin preparing for listing the Company’s share on Nasdaq Stockholm’s main market. The ambition is to complete the list change during the last quarter of 2021.“SynAct Pharma has worked hard with its pipeline to make it to where it is today. Moving to Nasdaq Stockholm’s main market is a stamp of quality,” said Jeppe Øvlesen, CEO of SynAct Pharma. “The move also gives us access to more international and institutional investors, who will be key